ReviewAustralian prescriber2024
Assessing, communicating and managing cardiovascular disease risk: a practical summary of the 2023 guideline.
Review in Australian prescriber, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.PharmacoEconomics · 2026Pooled it
- Effectiveness of quality improvement interventions in improving cardiovascular disease-related outcomes in primary and tertiary care: A systematic review and meta-analyses.BMC primary care · 2025Pooled it
- Quality of Available Cardiovascular Disease Knowledge Tools: A Systematic Review.Global heart · 2025Pooled it
- Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.JAMA cardiology · 2025Trial
- Feasibility and Preliminary Efficacy of an Online Cardiovascular Disease Prevention Randomised Controlled Trial Targeting Addictive and Compulsive Overeating Among Australian Young Adults.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Trial
- The effectiveness of medical nutrition therapy for people at moderate to high risk of cardiovascular disease in an Australian rural primary care setting: 12-month results from a pragmatic cluster randomised controlled trial.BMC health services research · 2025Trial
- Impact of provision of abdominal aortic calcification results on fruit and vegetable intake: 12-week randomized phase 2 controlled trial.Nature communications · 2024Trial
- Listen to Your Heart and Mind: A Pilot Mixed-Methods Study on Combined Screening for Raised Blood Pressure, Atrial Fibrillation, Cognitive Impairment and Hearing Loss in Older Adults.Australasian journal on ageing · 2026Article
- Association Between Hypertensive Disorders of Pregnancy, Lifestyle Factors, and Premature Cardiovascular Events.JACC. Advances · 2026Article
- Evaluating a Digital Chronic Condition Prevention Intervention (THRIVE) in Australian General Practice: Protocol for a Mixed Methods Feasibility Study (ePREVENT-360).JMIR research protocols · 2026Article
- Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment.JACC. Asia · 2026Review
- Community based interventions for the primary prevention of cardiovascular disease in women living in rural, regional and remote areas: a scoping review.BMC health services research · 2026Article
- The Extent and Nature of Lived Experience Engagement in the Development of Australian Clinical Practice Guidelines, 2014-2025: A Scoping Review.The Medical journal of Australia · 2026Article
- Screening for hypertension in a public dental clinic: A single-centre cross-sectional study in Australia.PloS one · 2026Article
- Artificial intelligence in fundus photography for type 2 diabetes: a scoping review of systemic biomarkers and multi-organ risk prediction.Frontiers in digital health · 2026Review
- Article
- Automated office blood pressure measurement: a Hypertension Australia and National Hypertension Taskforce of Australia position statement.Journal of hypertension · 2025Article
- Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary.The Medical journal of Australia · 2025Article
- Development and calibration of the 2023 Australian cardiovascular disease risk prediction equations: a model updating study.The Medical journal of Australia · 2025Article
- Co-Designing a Digital Stroke Prevention Platform: Leveraging Lived Experience and Expert Advice.Health expectations : an international journal of public participation in health care and health policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outdated cardiovascular disease risk calculator has been reported to overestimate cardiovascular disease risk for a contemporary Australian population, and does not include relevant variables, such as socioeconomic disadvantage, which has been shown to increase the incidence of both heart attack and stroke. The 2023 Australian Guideline for Assessing and Managing Cardiovascular Disease Risk marks a major milestone as the first update to Australia's cardiovascular disease prevention guideline in over a decade. The new guideline may help to refine and recategorise risk estimates, hence improving the discriminatory and predictive value of the new calculator. The new Australian Cardiovascular Disease Risk Calculator expresses risk scores as a percentage estimate of a person's probability of dying or being hospitalised due to cardiovascular disease within the next 5 years. The new calculator expresses risk scores as low (less than 5%), intermediate (5% to less than 10%), or high (10% or higher) risk over 5 years. Reclassification factors built into the new calculator are designed to help clinicians individualise risk estimates. These factors include ethnicity (e.g. First Nations status), family history of premature cardiovascular disease, severe mental illness, kidney disease and coronary artery calcium score. The new calculator also uses optional diabetes-specific variables (supporting a more granular cardiovascular disease risk assessment of people with type 2 diabetes). People who meet the clinically determined high-risk criteria (chronic kidney disease, familial hypercholesterolaemia) should not progress through the Australian Cardiovascular Disease risk calculator, but move straight to management. For a person with a cardiovascular disease risk score recorded from the outdated calculator, clinicians may want to reassess their risk using the new calculator the next time the person attends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.